Clinical Trial Update: A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity study of a plasmid DNA Prime and MVA Boost HIV vaccine in ART-treated HIV-1 infected adults has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MVA-based HIV vaccine (MVA-based HIV vaccine)
• plasmid DNA vaccine (HIV-1) (plasmid DNA vaccine)

Snippet

Sponsor: GeoVax, Inc. | Conditions: HIV-1 Infection | Phase 1 | Status: COMPLETED